Literature DB >> 7475142

Metastatic pattern in adenocarcinoma of the lung. An autopsy study from a cohort of 137 consecutive patients with complete resection.

L E Stenbygaard1, J B Sørensen, J E Olsen.   

Abstract

A cohort of 137 patients with completely resected stage I or II adenocarcinoma of the lung was observed from the time of operation; the metastatic pattern determined at autopsy is described in relation to clinical, histologic, and laboratory variables. The pretreatment variables evaluated were performance status, age, gender, lactate dehydrogenase, stage, degree of differentiation, and histologic subtype of adenocarcinoma of the lung. Patients who survived longer than 30 days after operation were eligible for analysis, and 35 autopsies were performed in this patient group (autopsy rate: 39.8%). The most common intrathoracic metastatic sites were mediastinal lymph nodes (43%), lung (31%), pleura (20%), pericardium (9%), and heart (6%). The most common extrathoracic sites were liver (37%), brain (33%), bones (21%), adrenals (17%), and kidneys (17%). Patients undergoing resection for stage I disease had significantly fewer intrathoracic metastases than patients with stage II disease (p = 0.01). Patients who survived less than 1 year had significantly more extrathoracic metastases than patients who survived for a longer period (p = 0.01). Patients with highly differentiated tumors had fewer extrathoracic metastases than patients with less differentiated tumors. No other statistically significant differences were observed. Overall, patients with stage I adenocarcinoma of the lung had better local control of the disease at autopsy than those with stage II disease, but distant metastases are a large problem despite the favorable prognosis of this patient group. The extrathoracic metastatic potential was greatest for less differentiated tumors. An active adjuvant systemic therapy after resection is needed in selected patients with poorly differentiated adenocarcinomas of the lung, even in those with stage I disease.

Entities:  

Mesh:

Year:  1995        PMID: 7475142     DOI: 10.1016/s0022-5223(05)80183-7

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  9 in total

1.  Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.

Authors:  Paul K Paik; Ronglai Shen; Helen Won; Natasha Rekhtman; Lu Wang; Camelia S Sima; Arshi Arora; Venkatraman Seshan; Marc Ladanyi; Michael F Berger; Mark G Kris
Journal:  Cancer Discov       Date:  2015-04-30       Impact factor: 39.397

2.  Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations.

Authors:  Toshihiko Iuchi; Masato Shingyoji; Meiji Itakura; Sana Yokoi; Yasumitsu Moriya; Hajime Tamura; Yasushi Yoshida; Hironori Ashinuma; Koichiro Kawasaki; Yuzo Hasegawa; Tsukasa Sakaida; Toshihiko Iizasa
Journal:  Int J Clin Oncol       Date:  2014-10-22       Impact factor: 3.402

3.  Liver metastasis at the time of initial diagnosis of lung cancer.

Authors:  Katsunori Kagohashi; Hiroaki Satoh; Hiroichi Ishikawa; Morio Ohtsuka; Kiyohisa Sekizawa
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

4.  Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model.

Authors:  Paul K Newton; Jeremy Mason; Kelly Bethel; Lyudmila Bazhenova; Jorge Nieva; Larry Norton; Peter Kuhn
Journal:  Cancer Res       Date:  2013-02-27       Impact factor: 12.701

5.  Simultaneous thigh muscle metastasis from lung cancer and Escherichia coli gas producing myonecrosis.

Authors:  Gonzalo E Martinez; Courtney A Coursey; Leslie Dodd; Salutario Martinez
Journal:  Skeletal Radiol       Date:  2008-05-22       Impact factor: 2.199

Review 6.  Adrenal metastases in lung cancer: clinical implications of a mathematical model.

Authors:  Lyudmila Bazhenova; Paul Newton; Jeremy Mason; Kelly Bethel; Jorge Nieva; Peter Kuhn
Journal:  J Thorac Oncol       Date:  2014-04       Impact factor: 15.609

7.  The landscape of metastatic progression patterns across major human cancers.

Authors:  Jan Budczies; Moritz von Winterfeld; Frederick Klauschen; Michael Bockmayr; Jochen K Lennerz; Carsten Denkert; Thomas Wolf; Arne Warth; Manfred Dietel; Ioannis Anagnostopoulos; Wilko Weichert; Daniel Wittschieber; Albrecht Stenzinger
Journal:  Oncotarget       Date:  2015-01-01

8.  Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers.

Authors:  M Ochiai; T Oguri; T Isobe; S Ishioka; M Yamakido
Journal:  Jpn J Cancer Res       Date:  1999-12

9.  Prognosis of EGFR-mutant advanced lung adenocarcinoma patients with different intrathoracic metastatic patterns.

Authors:  Fang Hu; Bo Zhang; Changhui Li; Jianlin Xu; Huimin Wang; Ping Gu; Xiaoxuan Zheng; Wei Nie; Yinchen Shen; Hai Zhang; Ping Hu; Xueyan Zhang
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.